Chimeric antigen receptors with modified linker domains and uses thereof
AssigneeBiosceptre (UK) Limited
InventorsKanchana Veronika Bandara, Justin Taylor Coombs, Timothy John Sadlon, Simon Charles Barry, Jade Hui Yu Foeng, Shaun Reuss McColl
Life of this patent
Estimating the term…
Abstract
The present invention relates to an optimized chimeric antigen receptor (CAR), and genetically modified cells expressing the same, that can target a diverse range of cancer types. More specifically, the CAR has an optimized linker length that facilitates the targeting and lyse of a wide range of cancer cell types by CAR expressing T cells.
Claims30
A chimeric antigen receptor including an antigen-recognition domain recognising a dysfunctional P2X7 receptor, a transmembrane domain and a linker domain, wherein the linker domain consists of between 12 to 228 amino acids.
17-18. (canceled)
20-21. (canceled)
(canceled)
25-27. (canceled)
(canceled)
32-34. (canceled)
36-37. (canceled)
39-51. (canceled)
54-58. (canceled)
60-64. (canceled)
Dependencies are inferred from the claim text.